Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Keytruda
Pharma
AZ's Imfinzi keeps MIBC race against Keytruda hot with FDA nod
AstraZeneca has crossed the finish line in MIBC with its own doublet wedding Pfizer and Astellas’ Padcev with its PD-L1 inhibitor Imfinzi.
Fraiser Kansteiner
Nov 13, 2026 5:40pm
For Merck, 2027 is ‘another year of investment’
Oct 29, 2026 11:23am
Merck sees ‘pretty consistent’ data in sac-TMT’s 1st global ph. 3
Oct 26, 2026 11:30am
Merck’s sac-TMT posts major PFS benefit in PD-L1-negative NSCLC
Oct 25, 2026 5:15am
ESMO: AstraZeneca pitches own Padcev combos in bladder cancer
Oct 24, 2026 10:30am
Halozyme wins Keytruda SC injunction in several European markets
Oct 7, 2026 11:08am